Renalytix AI plc is an artificial intelligence-enabled in vitro diagnostics company. It focuses on optimizing clinical management of kidney disease. Renalytix AI plc is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $2.29M |
| Net Income (Most Recent Fiscal Year) | $-33.46M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 14.08 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1191.50% |
| Net Margin (Trailing 12 Months) | -1191.75% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -341.71% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.24 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.25 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Health Information Services |
| Common Shares Outstanding | 165.60M |
| Free Float | 148.22M |
| Market Capitalization | $33.12M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 2.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |